Conference Call and Webcast at 8:30 AM Eastern Time
NEW
YORK, Oct. 31, 2024 /PRNewswire/ -- PAVmed
Inc. (Nasdaq: PAVM, PAVMZ) ("PAVmed" or the "Company"), a
diversified commercial-stage medical technology company, operating
in the medical device, diagnostics, and digital health sectors,
today announced that it will host a business update conference call
and webcast on Thursday, November 14,
2024, at 8:30 AM ET. During
the call, Lishan Aklog, M.D.,
PAVmed's Chairman and Chief Executive Officer, will provide a
business update including an overview of the Company's operations
and growth strategy. In addition, Dennis McGrath, PAVmed's President and Chief
Financial Officer, will discuss the Company's third quarter 2024
financial results.
The webcast will be available at the investor
relations section of the Company's website at pavmed.com.
Alternatively, to access the conference call by telephone,
U.S.-based callers should dial 1-800-836-8184 and international
listeners should dial 1-646-357-8785. All listeners should provide
the operator with the conference call name "PAVmed Business Update"
to join.
Following the conclusion of the conference call, a replay will
be available for 30 days on the investor relations section of the
Company's website at pavmed.com.
About PAVmed
PAVmed Inc. is a diversified
commercial-stage medical technology company operating in the
medical device, diagnostics, and digital health sectors. Its
subsidiary, Lucid Diagnostics (Nasdaq: LUCD), is a
commercial-stage cancer prevention medical diagnostics company that
markets the EsoGuard® Esophageal DNA Test and
EsoCheck® Esophageal Cell Collection Device—the
first and only commercial tools for widespread early detection of
esophageal precancer to mitigate the risks of esophageal cancer
deaths. Its other subsidiary, Veris Health Inc., is a digital
health company focused on enhanced personalized cancer care through
remote patient monitoring using implantable biologic sensors with
wireless communication along with a custom suite of connected
external devices. Veris is concurrently developing an implantable
physiological monitor, designed to be implanted alongside a
chemotherapy port, which will interface with the Veris Cancer Care
Platform.
For more and for more information about PAVmed, please
visit pavmed.com.
For more information about Lucid Diagnostics, please
visit luciddx.com.
For more information about Veris Health, please
visit verishealth.com.
View original content to download
multimedia:https://www.prnewswire.com/news-releases/pavmed-to-hold-a-business-update-conference-call-and-webcast-on-november-14-2024-302291561.html
SOURCE PAVmed Inc.